ישראל - עברית - Ministry of Health

rafa laboratories ltd - lansoprazole - קפסולות - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (gerd) or duodenal ulcer. prevention of relapse in patients with gerd or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - valaciclovir as hydrochloride - טבליות מצופות פילם - valaciclovir as hydrochloride 500 mg - valaciclovir - valaciclovir - valtrex is indicated for the treatment of herpes zoster (shingles) in immunocopotent adults.valtrex accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. the efficacy of valaciclovir in immunocompromised patients has not been established. valtrex is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. valtrex is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). prophylaxis of cytomegalovirus infection and disease, following organ transplantation. for the treatment of cold sores (herpes labialis).

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - piroxicam - ג'ל - piroxicam 5 mg/g - piroxicam - piroxicam - variety of conditions characterized by pain and inflammation such as osteoarthritis of superficial joints, acute musculoskeletal injuries, periarthritis, tendinitis and tenosynovitis.